<DOC>
	<DOCNO>NCT02405065</DOCNO>
	<brief_summary>The main objective study determine maximum tolerate dose ( MTD ) recommend phase 2 dose HM95573 .</brief_summary>
	<brief_title>Clinical Trial Evaluate Safety , Tolerability Pharmacokinetics Anti-tumor Activity HM95573</brief_title>
	<detailed_description>Besides main objective , 3 objective follow : - To evaluate anti-cancer effect HM95573 solid tumor patient - To investigate pharmacokinetic profile HM95573 oral administration . - To investigate biomarkers related safety efficacy HM95573 .</detailed_description>
	<criteria>Patients must 20 year age old Subjects provide voluntary consent participate study , sign write consent document . Estimated life expectancy least 12 week Histologically cytologically confirm advanced solid tumor Symptomatic uncontrolled central nervous system metastases Patients unable take tablet orally clinically significant gastrointestinal disorder , may interfere administration , metabolism absorption investigational drug . Patients , investigator 's opinion , suitable study reason .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>